Unicycive Therapeutics
Los Altos
About Unicycive Therapeutics
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $86.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2024)
- Ticker: nasdaq:UNCY
- Website: unicycive.com
- Phone: (650) 384-0642
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/unicycive-therapeutics-68593 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.